J.P. Morgan Healthcare Conference

J.P. Morgan Healthcare Conference January 12, 2023 Jim Clemmer, President &

CEO Stephen Trowbridge, Executive Vice President & CFO

2 Notice Regarding Forward-Looking Statements This presentation contains

forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy,

budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms,"

"intends," "anticipates," "plans," "projects," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of

future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results

achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors,

infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater

resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor

shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results

of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions,

general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or

approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31,

2022. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason. In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration

for use in the surgical ablation of soft tissue, and is similarly approved for commercialization in Canada, the European Union and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or

condition. Notice Regarding Non-GAAP Financial Measures Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics'

business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this presentation, AngioDynamics has

reported adjusted EBITDA (income before interest, taxes, depreciation and amortization and stock-based compensation); adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review

of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that

investors get a better picture of the performance of AngioDynamics' underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance

taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to

measures prepared in accordance with GAAP.

2 Notice Regarding Forward-Looking Statements This presentation contains

forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets,

projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends,"

"anticipates," "plans," "projects," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance

and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics

include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics'

technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or

other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges

including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product

recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance,

foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired

businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2022. AngioDynamics does not assume any obligation to

publicly update or revise any forward-looking statements for any reason. In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue, and is

similarly approved for commercialization in Canada, the European Union and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition. Notice Regarding Non-GAAP Financial

Measures Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics' business over time. Investors should consider these

non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this presentation, AngioDynamics has reported adjusted EBITDA (income before interest, taxes,

depreciation and amortization and stock-based compensation); adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these

measures provide investors with useful information in comparing AngioDynamics' performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics'

underlying business. Management encourages investors to review AngioDynamics' financial results prepared in accordance with GAAP to understand AngioDynamics' performance taking into account all relevant factors, including those that may only

occur from time to time but have a material impact on AngioDynamics' financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.

A medical technology platform company focused on a select group of large, high

growth markets where meaningful treatment gaps exist in current standard of care. Our technologies positively impact treatment options and patients' quality of life. AngioDynamics

4 AngioDynamicsInvestments in our Med Tech platforms are funded by operating cash

flows from our Med Device portfolio The planned portfolio additions and new indications are based on management estimates and industry sources as of July 2022 and are not guarantees of future performance and are subject to risks and

uncertainties including FDA clearance. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. FOCUSED TRANSFORMATION PURSUING ATTRACTIVE MARKETS U.S. Total Addressable Markets FY2021 -

$3.0B Launch of the Auryon System gives us access to the peripheral atherectomy market FY2023 - $6.0B Planned Thrombectomy & NanoKnife System portfolio additions & new indications increase market access FY2025 - $8.0B Planned

Thrombectomy & PE portfolio additions & new indications increase market access FY2018 - $1.3B Began our strategic initiative to become a growth company Med Tech: Invest for Growth Peripheral Arterial Disease Venous

Thromboembolism Cardiac Thrombus & Emboli Solid Tumor Med Device: Maintain Positioning Vascular Access Catheters & Accessories Microwave & Radiofrequency Ablation Diagnostic Catheters, Guidewires & Kits Lung Biopsy

Safety Endovenous Laser Treatment Radiation Treatment Stabilization Balloons

5 AngioDynamicsFocused technology platforms targeting attractive markets with

meaningful treatment gaps, where our differentiated technologies can address unmet needs Disease State Platform Treatment Status PAD Peripheral Arterial Disease Atherectomy Launched VTE Venous Thromboembolism Large Vessel

Thrombectomy Launched Launched Small Vessel Thrombectomy* In development with targeted launch end of calendar 2024 Pulmonary Embolism* APEX study currently enrolling Targeted launch early calendar 2025 Cardiac Thrombus &

Emboli Right Heart Left Heart* Launched Targeted launch end of calendar 2023 Clot in Transit Launched Solid Tumor Prostate Tissue* PRESERVE study >50% enrolled Launch targeted end of calendar 2024 *AlphaVac PE, Auryon Venous

Thrombectomy/DVT, AngioVac Left Heart & NanoKnife Prostate are not cleared by the US Food and Drug Administration (FDA) for these indications.

6 AngioDynamicsFocused technology platforms targeting attractive markets with

meaningful treatment gaps, where our differentiated technologies can address unmet needs Disease State Platform Treatment Status PAD Peripheral Arterial Disease Atherectomy Launched VTE Venous Thromboembolism Large Vessel

Thrombectomy Launched Launched Small Vessel Thrombectomy* In development with targeted launch end of calendar 2024 Pulmonary Embolism* APEX study currently enrolling Targeted launch early calendar 2025 Cardiac Thrombus &

Emboli Right Heart Left Heart* Launched Targeted launch end of calendar 2023 Clot in Transit Launched Solid Tumor Prostate Tissue* PRESERVE study >50% enrolled Launch targeted end of calendar 2024 *AlphaVac PE, Auryon Venous

Thrombectomy/DVT, AngioVac Left Heart & NanoKnife Prostate are not cleared by the US Food and Drug Administration (FDA) for these indications.

PADWith over 25,000 cases performed, the Auryon Atherectomy System is the only

atherectomy solution with the safety profile and versatility to treat every lesion location and morphology 7 Source: Peripheral Vascular Devices Medtech 360 Market Analysis US December, 2021. Millennium Research Group, Inc. Above the Knee

(ATK) Below the Knee (BTK) Office Based Lab (OBL) Hospital T H E M A R K E T O U R S O L U T I O N W H Y I T M A T T E R S Peripheral Atherectomy Protective of vessel wall c-e Targeted biological reactions to address risk of

perforations Built-in aspiration to address risk of embolization Built-in aspiration available with the 2.0-and 2.35-mm catheters. Treat all levels of calcification a-c Indicated for in-stent restenosis* Treats above and below the knee

(inc. below the ankle) *2.0mm and 2.35mm catheters are indicated for ISR. Designed for hospital and laba-c, f Portable, 110V outlet, low noise, touch screen Debulk in fewer passes 2022 Served $760M "We've always known that Auryon's

technology is one-of-a-kind and unmatched. With the new [hydrophilic coating], we should be able to prove this - case after case after case" - Dr. Curtis Anderson, Vascular & Interventional Radiologist a-f See reference page

8 AngioDynamicsFocused technology platforms targeting attractive markets with

meaningful treatment gaps, where our differentiated technologies can address unmet needs Disease State Platform Treatment Status PAD Peripheral Arterial Disease Atherectomy Launched VTE Venous Thromboembolism Large Vessel

Thrombectomy Launched Launched Small Vessel Thrombectomy* In development with targeted launch end of calendar 2024 Pulmonary Embolism* APEX study currently enrolling Targeted launch early calendar 2025 Cardiac Thrombus &

Emboli Right Heart Left Heart* Launched Targeted launch end of calendar 2023 Clot in Transit Launched Solid Tumor Prostate Tissue* PRESERVE study >50% enrolled Launch targeted end of calendar 2024 *AlphaVac PE, Auryon Venous

Thrombectomy/DVT, AngioVac Left Heart & NanoKnife Prostate are not cleared by the US Food and Drug Administration (FDA) for these indications.

VTEOur differentiated technology platforms offer potential treatment solutions

across the entire disease state 9 Source: Management estimate & industry sources as of July 2022. *AlphaVac PE and Auryon Venous Thrombectomy/DVT are not cleared by the US FDA for these indications.

$2.1B $1.8B PULMONARY EMBOLISM* DEEP VEIN THROMBOSIS DVT A blood clot that forms in a deep vein, usually the leg, groin or arm Deep Vein Thrombosis Pulmonary Embolism PE A DVT breaks free and travels to the lungs blocking some or

all of the blood supply Venous Thromboembolism VTE DVT and PE are collectively referred to as VTE + = T H E M A R K E T O U R S O L U T I O N W H Y I T M A T T E R S Only solution on the market with continuous aspiration and

simultaneous reinfusion of filtered blood Aspirates large clot burden Controlled aspiration Aspirates large clot burden APEX-AV study for PE Auryon's combination of laser technology and aspiration restores flow in occluded vessels Large

Vessel Venous Thrombectomy/DVT Large Vessel Venous Thrombectomy/DVT Pulmonary Embolism* Small Vessel Venous Thrombectomy/DVT* 2022 TAM $3.9B

VTEAll-purpose technology platforms targeted at peripheral and cardiovascular

thrombolytic events, including small and large vessels PRECISE Protective of vessel wallc-e ADAPTABLE Potential to treat all types of small vessel DVT* POWERFUL 355 nm laser is designed to deliver an optimized wavelength, pulse width, and

amplitude to restore flow in occluded vesselsc, d, g Small Vessel The AngioVac System allows for the continuous aspiration of embolic material such as thrombi and emboli from the venous system while Simultaneously reinfusing the patient's own

filtered blood to limit procedural blood loss MULTIPLE TIP ANGLES 200, 850, 1800 Proprietary Funnel Design Allows for Significant Clot Removal Radiopaque Markers Better Tip Visibility Large End Hole Aspiration 42FR & 30FR

Opening The AlphaVac System allows for the controlled aspiration of embolic material such as thrombi and emboli from the venous system Large Vessel c-g See reference page *Auryon Venous Thrombectomy/DVT is not cleared by the US FDA for this

11 AngioDynamicsFocused technology platforms targeting attractive markets with

meaningful treatment gaps, where our differentiated technologies can address unmet needs Disease State Platform Treatment Status PAD Peripheral Arterial Disease Atherectomy Launched VTE Venous Thromboembolism Large Vessel

Thrombectomy Launched Launched Small Vessel Thrombectomy* In development with targeted launch end of calendar 2024 Pulmonary Embolism* APEX study currently enrolling Targeted launch early calendar 2025 Cardiac Thrombus &

Emboli Right Heart Left Heart* Launched Targeted launch end of calendar 2023 Clot in Transit Launched Solid Tumor Prostate Tissue* PRESERVE study >50% enrolled Launch targeted end of calendar 2024 *AlphaVac PE, Auryon Venous

Thrombectomy/DVT, AngioVac Left Heart & NanoKnife Prostate are not cleared by the US Food and Drug Administration (FDA) for these indications.

Cardiac Thrombus & EmboliWe are focused on offering percutaneous solutions for

removing thrombus and emboli in the left and right heart 12 RIGHT HEART LEFT HEART $450M $80M Right Heart Left Heart* T H E M A R K E T O U R S O L U T I O N W H Y I T M A T T E R S 2022 TAM $530M Source: Management estimate &

industry sources as of July 2022. *AngioVac Left Heart is not cleared by the US FDA for this indication. Continuous aspiration combined with the funnel tip, allows for the efficient removal of the targeted material while minimizing risk of

blood loss Currently, there is no standard for right or left heart percutaneous approach

13 AngioDynamicsFocused technology platforms targeting attractive markets with

meaningful treatment gaps, where our differentiated technologies can address unmet needs Disease State Platform Treatment Status PAD Peripheral Arterial Disease Atherectomy Launched VTE Venous Thromboembolism Large Vessel

Thrombectomy Launched Launched Small Vessel Thrombectomy* In development with targeted launch end of calendar 2024 Pulmonary Embolism* APEX study currently enrolling Targeted launch early calendar 2025 Cardiac Thrombus &

Emboli Right Heart Left Heart* Launched Targeted launch end of calendar 2023 Clot in Transit Launched Solid Tumor Prostate Tissue* PRESERVE study >50% enrolled Launch targeted end of calendar 2024 *AlphaVac PE, Auryon Venous

Thrombectomy/DVT, AngioVac Left Heart & NanoKnife Prostate are not cleared by the US Food and Drug Administration (FDA) for these indications.

Prostate Initiative*Over 100,000 men with intermediate risk prostate cancer could

be treated with this technology 14 *IDE Study in progress Market Source: Management estimate & industry sources as of July 2022. Focal Therapy T H E M A R K E T O U R S O L U T I O N W H Y I T M A T T E R S 2022